PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
April 5, 2026Cancer Research

Abstract 5299: Epigenetic modulation by MDM2 and DNMT inhibitor promotes cell cycle arrest and programmed cell death in neuroblastoma cells

View Full Paper
Ask AI
Bookmark
Share

Authors

STSruthika TalankiHLHoa LeACAashi Chhabra

Discussion

Loading...

Member takes

Overview

Demonstrates that MDM2 and DNMT inhibitors trigger cell cycle arrest and apoptosis in neuroblastoma cells, indicating a new treatment strategy.

Key Points

  • This research aims to explore the effects of MDM2 and DNMT inhibitors on cell cycle arrest and apoptosis in neuroblastoma cells.
  • Utilized RG-7388, CM-272, and SGI-1027 to treat IMR-32 and SK-N-AS neuroblastoma cells for 24 hours.
  • Conducted qRT-PCR to evaluate gene expression of various epigenetic and apoptotic markers.
  • Performed western blot analysis to assess protein expression related to cell cycle and apoptosis.
  • Downregulation of DNMT-1, DNMT-3A, DNMT-3B, G9a, and EZH2 was observed in CM-272 and SGI-1027 treated SK-N-AS cells.
  • Western blot showed downregulation of DNMT-1, cleavage of PARP, and upregulation of BAX in both cell lines.
  • MDM2 and DNMT inhibitors effectively induced cell cycle arrest and apoptosis, suggesting potential as therapeutic agents.

Cite This Study

Talanki et al. (2026) studied this question.

synapsesocial.com/papers/69d1fcc0a79560c99a0a273bhttps://doi.org/10.1158/1538-7445.am2026-5299
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Abstract 2865: Efficacy of MDM2 and epigenetic inhibitors treatments for neuroblastoma2024
  2. 2Abstract 5294: Epigenetic modulation by DNMT-1 inhibitor induces cell death in SK-N-AS neuroblastoma cells2026
  3. 3Abstract 7066: Comparative <i>in vivo</i> evaluation of RG-7388, CM-272, and SGI-1027 to determine epigenetic targeting as an effective strategy for treating high-risk neuroblastoma.2026
  4. 4Abstract 5785: RBM39 degrader anticancer activity against neuroblastoma: CDKN2A/B deletion as a biomarker2026
  5. 5Abstract 4568: Inhibition of nicotinamide phosphoribosyltransferase (NAMPT) impairs cellular viability, affects energy metabolism, induces DNA damage, and drives tumor regression in preclinical models of neuroblastoma2026